Annals of Oncology 11:721-728, 2000
© 2000 European Society for Medical Oncology
research-article |
A phase I–II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer
University of Chicago Chicago, Illinois, USA
Correspondence to: B. Brockstein, MD, Assistant Professor of Medicine, Northwestern University, Evanston Northwestern Healthcare, Hematology/Oncology, 2650 Ridge, Evanston, IL 60201. USA. E-mail: b-brockstein{at}nwu.edu
Background: Concomitant chemoradiotherapy is an effective treatment modality for advanced head and neck cancer, but improved regimens are needed. We sought to define the toxicities, recommended phase II dose, and outcome of a combination chemotherapy regimen with concomitant hyperfractionated radiotherapy in patients with poor prognosis cancers of the head and neck, including those having received prior curative intent radiotherapy.
Patients and methods: From 1995 until 1997, 54 patients were treated, 25 of whom had received a prior full course of radiotherapy to the head and neck. Patients were treated with 5-fluorouracil (5-FU) 600 mg/m2/day continuous infusion x 5 days (days 1–5), hydroxyurea, 500 mg p.o. bid x 11 doses (days 1–6) and paclitaxel (60–150 mg/m2) by one-hour infusion on day 2 using a dose escalation strategy. Radiotherapy was given concomitantly on days 2–6, 150 cGy bid. Each of 4–5 cycles was delivered every other week.
Results: The MTD of paclitaxel was 100 mg/m2. The regimen was feasible; radiotherapy was delivered at a median of 7300 cGy and 83% of patients received 
80% planned dose intensity. Hematological toxicity, with granulocyte colony stimulating factor, was very mild. Dose limiting toxicities were mucositis and dermatitis. Despite poor prognosis, two-year survival was 45%.
Conclusions: The recommended phase II dose of this regimen is 5-FU 600 mg/m2/day x 120 hours (days 1–5), hydroxyurea 500 mg p.o. b.i.d. x 11 doses (days 1–6), paclitaxel 100 mg/m2 over one hour on day 2, and radiotherapy 150 cGy b.i.d. days 2–6. Concomitant chemotherapy and re-irradiation was feasible on this protocol and resulted in long-term survival in patients without other curative intent options.
chemotherapy, concomitant chemoradiotherapy, head and neck cancer, paclitaxel, radiation, reirradiation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Y. Seiwert, D. J. Haraf, E. E.W. Cohen, K. Stenson, M. E. Witt, A. Dekker, M. Kocherginsky, R. R. Weichselbaum, H. X. Chen, and E. E. Vokes Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1732 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. C. Wong, R. A. Soo, J. J. Lu, K. S. Loh, K. S. Tan, W. S. Hsieh, T. P. Shakespeare, E. T. Chua, H. L. Lim, and B. C. Goh Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma Ann. Onc., July 1, 2006; 17(7): 1152 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Haraf, F. R. Rosen, K. Stenson, A. Argiris, B. B. Mittal, M. E. Witt, B. E. Brockstein, M. A. List, L. Portugal, H. Pelzer, et al. Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5936 - 5943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Argiris, D. J. Haraf, M. S. Kies, and E. E. Vokes Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure Oncologist, August 1, 2003; 8(4): 350 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Rosen, D. J. Haraf, M. S. Kies, K. Stenson, L. Portugal, M. A. List, B. E. Brockstein, B. B. Mittal, A. W. Rademaker, M. E. Witt, et al. Multicenter Randomized Phase II Study of Paclitaxel (1-Hour Infusion), Fluorouracil, Hydroxyurea, and Concomitant Twice Daily Radiation with or without Erythropoietin for Advanced Head and Neck Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1689 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Vokes, K. Stenson, F. R. Rosen, M. S. Kies, A. W. Rademaker, M. E. Witt, B. E. Brockstein, M. A. List, B. B. Fung, L. Portugal, et al. Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer J. Clin. Oncol., January 15, 2003; 21(2): 320 - 326. [Abstract] [Full Text] [PDF]
|
|